Stock EFTR EFFECTOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
2.2 USD +1.85% Intraday chart for eFFECTOR Therapeutics, Inc. +16.40% -81.17%
04/04 Health Care Down on Retreat From Risk -- Health Care Roundup DJ
04/04 Top Midday Decliners MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Decliners
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Top Premarket Decliners
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia
EFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
EFFECTOR Therapeutics Closes $16.2 Million Registered Direct Offering, Private Placement
EFFECTOR Therapeutics Launches $8.7 Million Registered Direct Offering
EFFECTOR Therapeutics Expects to Raise $7.5 Million in Gross Proceeds From Registered Direct Offering; Shares Rise
Sector Update: Health Care Stocks Climb Pre-Bell Friday
Sector Update: Health Care
Debt Talks Progress Lift Exchange-Traded Funds, Equity Futures Pre-Bell Friday
EFFECTOR Reports 'Positive' Data Updates in Mid-Stage Breast Cancer Trial; Shares Soar After-Hours
EFFECTOR Therapeutics, Inc. Announces Positive Interim Data Updates from Phase 2 Expansion Cohort Evaluating Zotatifin Combined with Fulfvestrant and Abemaciclib
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. News eFFECTOR Therapeutics, Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW